Aptose Biosciences (APTO) said Tuesday the Nasdaq Hearings Panel has decided to delist its shares from the stock exchange on Wednesday due to the company's failure to comply with the equity requirement for continued listing.
The company said it was unable to regain compliance by March 31.
Aptose said it will review "all available options, including an appeal to the determination" and will apply to list on a US national securities exchange "at the appropriate time."
The company's shares were falling more than 51% in recent trading.
Price: 1.54, Change: -1.63, Percent Change: -51.41
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。